TABLE 4.

In vitro activity of 3′-azido analogs against HIV-1 RT with the K65R mutation

Compound	Mean IC50 (μM) ± SDa			P
	HIV-1WT	HIV-165R	Fold changeb
AZA	3.92 ± 1.1	3.72 ± 0.30	0.9	0.89
AZGc	7.90 ± 4.63	15.8 ± 9.8	2.0	0.09
AZCc	15.0 ± 10.7	37.8 ± 28.5	2.5	0.05
AZT	0.20 ± 0.12	0.22 ± 0.16	1.1	0.77

^aMeans ± standard deviations from at least three independent experiments.

^bFold change relative to wild-type results.

^cAssay done using MT-2 cells.